Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy
Recruitment status was: Recruiting
Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed “idiopathic detachment of the macula” in 1866, is a well-characterized disorder leading to serous neurosensory elevation of the central macula. The acute form of the disease is associated with focal leakage at the level of the retinal pigment epithelium (RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the majority of patients, who also regain excellent vision. Occasionally, the neurosensory detachment persists and leads to pigment epithelial and photoreceptor damage with visual impairment.
The purpose of this clinical study is report the use of intravitreal bevacizumab is a new option in the treatment of the chronic or recurrent CSC.
Central Serous Chorioretinopathy
Drug: Intravitreal injection of Bevacizumab
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Please refer to this study by its ClinicalTrials.gov identifier: NCT00418431
|Asociacion para Evitar la Ceguera en Mexico|
|Mexico DF, DF, Mexico, 04030|
|Principal Investigator:||Mitzy E Torres Soriano, MD||APEC|